Phio Pharmaceuticals (PHIO) Q3 2026 earnings summary

Executive summary

• PH-762 advanced toward a planned Phase 2b neoadjuvant study in cSCC, expected to begin in Q1 2027, subject to FDA feedback.

• Phase 1b enrolled 22 patients and was completed in June 2026; Q3 operating expenses rose to $4.268 million and net loss was $4.160 million.

Financial highlights

• Q3 operating expenses were $4.268 million versus $2.505 million YoY; net loss was $4.160 million versus $2.392 million, with no revenue generated.

• Nine-month operating expenses were $12.703 million versus $6.686 million YoY; net loss was $12.301 million versus $6.327 million.

• Cash and cash equivalents were $10.609 million at September 30, 2026, versus $21.031 million at December 31, 2025.

Outlook and guidance

• FDA feedback on PH-762’s proposed development strategy was expected by the end of November 2026; Phase 2b initiation in cSCC was expected in Q1 2027.

• PH-762 clinical supply manufacturing was expected in Q4 2026; a preliminary report from the pivotal GLP toxicology study was expected before year-end 2026.

• Existing cash may not fund operations for at least 12 months from the financial statements’ release; additional capital is required to support operations and development.